Signal Transduction and Targeted Therapy invites submissions advancing cancer biology, signaling, and translational research.
Submit your work here:
mts-sigtrans.nature.com
#LungCancerResearch #CancerSignaling
Submit your work here:
mts-sigtrans.nature.com
#LungCancerResearch #CancerSignaling
January 27, 2026 at 10:33 AM
Signal Transduction and Targeted Therapy invites submissions advancing cancer biology, signaling, and translational research.
Submit your work here:
mts-sigtrans.nature.com
#LungCancerResearch #CancerSignaling
Submit your work here:
mts-sigtrans.nature.com
#LungCancerResearch #CancerSignaling
Why does #LungCancerResearch matter to you?
Share your reason below. ⬇️ Then urge Congress to advance S.1157, the Women and Lung Cancer Research and Preventive Services Act.
Take action via VoterVoice: go2.org/advocacy/tak...
Share your reason below. ⬇️ Then urge Congress to advance S.1157, the Women and Lung Cancer Research and Preventive Services Act.
Take action via VoterVoice: go2.org/advocacy/tak...
January 13, 2026 at 8:47 PM
Why does #LungCancerResearch matter to you?
Share your reason below. ⬇️ Then urge Congress to advance S.1157, the Women and Lung Cancer Research and Preventive Services Act.
Take action via VoterVoice: go2.org/advocacy/tak...
Share your reason below. ⬇️ Then urge Congress to advance S.1157, the Women and Lung Cancer Research and Preventive Services Act.
Take action via VoterVoice: go2.org/advocacy/tak...
This Sunday (Dec 14), Jesse Boehm returns to #ALKtALK with updates on Break Through Cancer's PowerRD 2 Cure ALK+ Lung Cancer TeamLab.
Join live for the latest progress + Q&A.
#ALKPositive #LungCancerResearch #MoreResearchMoreTime
Join live for the latest progress + Q&A.
#ALKPositive #LungCancerResearch #MoreResearchMoreTime
December 12, 2025 at 1:30 PM
This Sunday (Dec 14), Jesse Boehm returns to #ALKtALK with updates on Break Through Cancer's PowerRD 2 Cure ALK+ Lung Cancer TeamLab.
Join live for the latest progress + Q&A.
#ALKPositive #LungCancerResearch #MoreResearchMoreTime
Join live for the latest progress + Q&A.
#ALKPositive #LungCancerResearch #MoreResearchMoreTime
We're grateful for the scientific discoveries and continued progress made possible by funding #LungCancerResearch. Learn about recent approvals for treatment: LCRF.org/FDA. Fund more research this Lung Cancer Awareness Month! LCRF.org/LCAMyourWay #LCAM
November 24, 2025 at 4:45 PM
We're grateful for the scientific discoveries and continued progress made possible by funding #LungCancerResearch. Learn about recent approvals for treatment: LCRF.org/FDA. Fund more research this Lung Cancer Awareness Month! LCRF.org/LCAMyourWay #LCAM
#FridayFacts: #LungCancerResearch saves lives! More treatments were developed in the past decade than in the 7 decades before. Let's keep that trend going! Find out how you can help: LCRF.org/LCAM. #LCAM2025
November 22, 2025 at 3:45 PM
#FridayFacts: #LungCancerResearch saves lives! More treatments were developed in the past decade than in the 7 decades before. Let's keep that trend going! Find out how you can help: LCRF.org/LCAM. #LCAM2025
Take a walk in the park on Sunday, Nov. 9 to benefit #lungcancerresearch. The #CaseCancerInitiative will be waiting for you to join them at Willard Park. Details below. #caseccc #cci #kickcancer #cwrusom #lungevity
November 7, 2025 at 7:02 PM
Take a walk in the park on Sunday, Nov. 9 to benefit #lungcancerresearch. The #CaseCancerInitiative will be waiting for you to join them at Willard Park. Details below. #caseccc #cci #kickcancer #cwrusom #lungevity
We’ll be following how these subgroup analyses help define the role of PD-(L)1 x VEGF bispecifics in this dynamic and evolving space.
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
SITC 2025 – Oncology Resource Group
onc-rg.com
October 30, 2025 at 7:42 PM
We’ll be following how these subgroup analyses help define the role of PD-(L)1 x VEGF bispecifics in this dynamic and evolving space.
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
Synapse: Your Connection to our MSK Authors
Meet: Rastko Rakocevic
Research Focus: Medicine; Assistant Attending L1
Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma
synapse.mskcc.org/synapse/work...
#RoboticBronchoscopy #LungCancerResearch
Meet: Rastko Rakocevic
Research Focus: Medicine; Assistant Attending L1
Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma
synapse.mskcc.org/synapse/work...
#RoboticBronchoscopy #LungCancerResearch
September 18, 2025 at 2:53 PM
Synapse: Your Connection to our MSK Authors
Meet: Rastko Rakocevic
Research Focus: Medicine; Assistant Attending L1
Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma
synapse.mskcc.org/synapse/work...
#RoboticBronchoscopy #LungCancerResearch
Meet: Rastko Rakocevic
Research Focus: Medicine; Assistant Attending L1
Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma
synapse.mskcc.org/synapse/work...
#RoboticBronchoscopy #LungCancerResearch
Respiratory physician and PHD candidate Anna McLean was the successful recipient of our Rosemary Holmes Travel Grant. Thanks to this grant Anna attended #WCLC in Barcelona and had an abstract accepted!
Check out what opportunities for funding are coming up: buff.ly/7QIbJ6d
#LungCancerResearch
Check out what opportunities for funding are coming up: buff.ly/7QIbJ6d
#LungCancerResearch
September 18, 2025 at 9:01 AM
Respiratory physician and PHD candidate Anna McLean was the successful recipient of our Rosemary Holmes Travel Grant. Thanks to this grant Anna attended #WCLC in Barcelona and had an abstract accepted!
Check out what opportunities for funding are coming up: buff.ly/7QIbJ6d
#LungCancerResearch
Check out what opportunities for funding are coming up: buff.ly/7QIbJ6d
#LungCancerResearch
Dr. Jacob Kaufman explains how each biomarker in lung cancer can lead to a treatment designed specifically for patients with that marker. Learn more about the impact of biomarker testing in lung cancer today: buff.ly/OpJwidX
#LungCancer #Biomarker #LungCancerResearch
#LungCancer #Biomarker #LungCancerResearch
September 13, 2025 at 6:15 PM
Dr. Jacob Kaufman explains how each biomarker in lung cancer can lead to a treatment designed specifically for patients with that marker. Learn more about the impact of biomarker testing in lung cancer today: buff.ly/OpJwidX
#LungCancer #Biomarker #LungCancerResearch
#LungCancer #Biomarker #LungCancerResearch
🛎️ Auction extended to Sept 21!
Support lung cancer research and score amazing prizes, from a Maui escape to mentoring with Dr. David Carbone.
💙 All proceeds support early-career investigators via the IASLC Foundation.
Bid before Sept 21: bit.ly/47H0swO
#IASLC #AuctionForACause #LungCancerResearch
Support lung cancer research and score amazing prizes, from a Maui escape to mentoring with Dr. David Carbone.
💙 All proceeds support early-career investigators via the IASLC Foundation.
Bid before Sept 21: bit.ly/47H0swO
#IASLC #AuctionForACause #LungCancerResearch
September 12, 2025 at 2:47 PM
🛎️ Auction extended to Sept 21!
Support lung cancer research and score amazing prizes, from a Maui escape to mentoring with Dr. David Carbone.
💙 All proceeds support early-career investigators via the IASLC Foundation.
Bid before Sept 21: bit.ly/47H0swO
#IASLC #AuctionForACause #LungCancerResearch
Support lung cancer research and score amazing prizes, from a Maui escape to mentoring with Dr. David Carbone.
💙 All proceeds support early-career investigators via the IASLC Foundation.
Bid before Sept 21: bit.ly/47H0swO
#IASLC #AuctionForACause #LungCancerResearch
🚀 #WCLC 2025: DLL3-Directed therapy shows encouraging results in relapsed SCLC. Phase I trial of SHR-4849 reached 59.5% overall response and up to 77.8% at higher doses, without dose-limiting toxicities.
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
WCLC 2025: DLL3 Therapy Shows Promise in Relapsed SCLC
A Phase 1 trial of the DLL3-targeted antibody-drug conjugate SHR-4849 shows high response rates and manageable safety in relapsed small cell lung cancer, supporting further clinical development.
www.emjreviews.com
September 9, 2025 at 6:34 PM
🚀 #WCLC 2025: DLL3-Directed therapy shows encouraging results in relapsed SCLC. Phase I trial of SHR-4849 reached 59.5% overall response and up to 77.8% at higher doses, without dose-limiting toxicities.
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
Summit Therapeutics' lung cancer drug, ivonescimab, showed varying efficacy in a recent study. China saw a 45% risk reduction, while Western results were not statistically significant. #LungCancerResearch #News
Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster
Summit Therapeutics' lung cancer drug, ivonescimab, showed varying efficacy in a recent study. Chin...
www.statnews.com
September 7, 2025 at 10:08 PM
Summit Therapeutics' lung cancer drug, ivonescimab, showed varying efficacy in a recent study. China saw a 45% risk reduction, while Western results were not statistically significant. #LungCancerResearch #News
Not every patient responds to immunotherapy in the same way. Dr. Kellie Smith explains which lung cancers are more likely to benefit and how doctors use testing to guide treatment decisions. Watch the full video here: buff.ly/OqAoIZh
#Immunotherapy #LungCancerResearch #LungCancer
#Immunotherapy #LungCancerResearch #LungCancer
September 7, 2025 at 6:15 PM
Not every patient responds to immunotherapy in the same way. Dr. Kellie Smith explains which lung cancers are more likely to benefit and how doctors use testing to guide treatment decisions. Watch the full video here: buff.ly/OqAoIZh
#Immunotherapy #LungCancerResearch #LungCancer
#Immunotherapy #LungCancerResearch #LungCancer
Immunotherapy helps the immune system recognize and attack cancer cells. New research shows patients are seeing durable results that last long after treatment begins. Learn more about how this groundbreaking approach is advancing cancer treatment: buff.ly/Vgr158e
#Immunotherapy #LungCancerResearch
#Immunotherapy #LungCancerResearch
September 5, 2025 at 6:15 PM
Immunotherapy helps the immune system recognize and attack cancer cells. New research shows patients are seeing durable results that last long after treatment begins. Learn more about how this groundbreaking approach is advancing cancer treatment: buff.ly/Vgr158e
#Immunotherapy #LungCancerResearch
#Immunotherapy #LungCancerResearch
At the IASLC 2025 Hot Topic Meeting, we’re diving into the biology, biomarkers, and breakthroughs that can transform prevention and treatment.
Join the conversation shaping the future of lung cancer research.
Register now: bit.ly/4oEkZIq
#LungCancerResearch #Oncology #HT25
Join the conversation shaping the future of lung cancer research.
Register now: bit.ly/4oEkZIq
#LungCancerResearch #Oncology #HT25
August 15, 2025 at 2:35 PM
At the IASLC 2025 Hot Topic Meeting, we’re diving into the biology, biomarkers, and breakthroughs that can transform prevention and treatment.
Join the conversation shaping the future of lung cancer research.
Register now: bit.ly/4oEkZIq
#LungCancerResearch #Oncology #HT25
Join the conversation shaping the future of lung cancer research.
Register now: bit.ly/4oEkZIq
#LungCancerResearch #Oncology #HT25
Lung Cancer Incidence in Counties at Low and High Risk of Radon Exposure: A Population-Based SEER Analysis (1975-2022)
Maxfield, N., Semprini, J.
Paper
Details
#RadonExposure #LungCancerResearch #SEERAnalysis
Maxfield, N., Semprini, J.
Paper
Details
#RadonExposure #LungCancerResearch #SEERAnalysis
August 12, 2025 at 4:03 PM
Lung Cancer Incidence in Counties at Low and High Risk of Radon Exposure: A Population-Based SEER Analysis (1975-2022)
Maxfield, N., Semprini, J.
Paper
Details
#RadonExposure #LungCancerResearch #SEERAnalysis
Maxfield, N., Semprini, J.
Paper
Details
#RadonExposure #LungCancerResearch #SEERAnalysis
🔬 At TRACKER, we’ve future‑proofed our lung cancer biobank.
By storing samples in multiple formats with NGS applications in mind, we’re ensuring today’s donations power tomorrow’s breakthroughs!
🌏 More: www.trackerbiobank.com
#LungCancerResearch #FutureProofing #ResearchwithImpact
By storing samples in multiple formats with NGS applications in mind, we’re ensuring today’s donations power tomorrow’s breakthroughs!
🌏 More: www.trackerbiobank.com
#LungCancerResearch #FutureProofing #ResearchwithImpact
August 7, 2025 at 11:00 PM
🔬 At TRACKER, we’ve future‑proofed our lung cancer biobank.
By storing samples in multiple formats with NGS applications in mind, we’re ensuring today’s donations power tomorrow’s breakthroughs!
🌏 More: www.trackerbiobank.com
#LungCancerResearch #FutureProofing #ResearchwithImpact
By storing samples in multiple formats with NGS applications in mind, we’re ensuring today’s donations power tomorrow’s breakthroughs!
🌏 More: www.trackerbiobank.com
#LungCancerResearch #FutureProofing #ResearchwithImpact
📚 Congratulations to Dr Sarah Yeo, lead author of TRACKER Biobank's first peer-reviewed publication, which explores the challenges and future directions for lung cancer biobanking in Australia.
Read the review here: ow.ly/jlvA50Wze5Y
#LungCancerResearch #CancerResearch #Biobank #ONJCRI
Read the review here: ow.ly/jlvA50Wze5Y
#LungCancerResearch #CancerResearch #Biobank #ONJCRI
August 5, 2025 at 4:00 AM
📚 Congratulations to Dr Sarah Yeo, lead author of TRACKER Biobank's first peer-reviewed publication, which explores the challenges and future directions for lung cancer biobanking in Australia.
Read the review here: ow.ly/jlvA50Wze5Y
#LungCancerResearch #CancerResearch #Biobank #ONJCRI
Read the review here: ow.ly/jlvA50Wze5Y
#LungCancerResearch #CancerResearch #Biobank #ONJCRI
Lung cancer has a 5-year survival rate of only 28 percent—lower than breast, prostate, or colorectal cancer. Most cases are diagnosed too late, when treatment options are limited. Awareness and early detection can change that. Learn more here: buff.ly/wdORvLN
#LungCancer #LungCancerResearch #LCFA
#LungCancer #LungCancerResearch #LCFA
August 2, 2025 at 6:15 PM
Lung cancer has a 5-year survival rate of only 28 percent—lower than breast, prostate, or colorectal cancer. Most cases are diagnosed too late, when treatment options are limited. Awareness and early detection can change that. Learn more here: buff.ly/wdORvLN
#LungCancer #LungCancerResearch #LCFA
#LungCancer #LungCancerResearch #LCFA
🫁 Lung cancer is the leading cause of cancer death worldwide. On #WorldLungCancerDay, we reaffirm our commitment to changing the way cancer is treated.
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
NSCLC TIL Cell Therapy Trial: IOV-LUN-202 | Iovance Biotherapeutics
This trial is enrolling people with non-small cell lung cancer that has progressed on previous chemoimmunotherapy and is metastatic. See the eligibility criteria, what to expect and find a nearby tria...
www.tilcelltherapy.com
August 1, 2025 at 2:00 PM
🫁 Lung cancer is the leading cause of cancer death worldwide. On #WorldLungCancerDay, we reaffirm our commitment to changing the way cancer is treated.
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
Today is World Lung Cancer Day. Join us live from 9 AM to 1 PM PT on Facebook and YouTube for thoughtful conversations and new insights. Their experiences remind us why this work matters. Learn more: buff.ly/Foih3L9
#WLCD #WLCD25 #WorldLungCancerDay #LCFA #LungCancerResearch #LivingWithLungCancer
#WLCD #WLCD25 #WorldLungCancerDay #LCFA #LungCancerResearch #LivingWithLungCancer
August 1, 2025 at 1:15 PM
Today is World Lung Cancer Day. Join us live from 9 AM to 1 PM PT on Facebook and YouTube for thoughtful conversations and new insights. Their experiences remind us why this work matters. Learn more: buff.ly/Foih3L9
#WLCD #WLCD25 #WorldLungCancerDay #LCFA #LungCancerResearch #LivingWithLungCancer
#WLCD #WLCD25 #WorldLungCancerDay #LCFA #LungCancerResearch #LivingWithLungCancer
